Do immune checkpoint inhibitors work in EGFR mutant lung cancer?
Dr Edward Garon - UCLA Medical Center, Santa Monica, USA
22 May 2020
COVID-19: Risk of millions relapsing back to smoking
Dr Sudhanshu Patwardhan - Centre for Health Research and Education, Southampton,...
22 May 2020
TERAVOLT: Thoracic cancers indicate an unexpectedly high mortality rate in patie...
Dr Heather Wakelee - Stanford University Medical Center, Stanford, USA
21 May 2020
COVID-19: Management of non-small cell lung cancer patients during the coronavir...
Dr Heather Wakelee - Stanford University, Stanford, USA
12 May 2020
Prostate cancer patients receiving androgen-deprivation therapies shown to be at...
Prof Andrea Alimonti - Università della Svizzera Italiana, Bellinzona, Switzerla...
7 May 2020
COVID-19: The situation in Florida and managing lung cancer patients
Dr. Luis Raez - Memorial Healthcare System, Florida, Miami
27 Apr 2020
New oncogenic drivers in NSCLC
Prof Egbert Smit - Netherlands Cancer Institute, Amsterdam, Netherlands
23 Apr 2020
The potential of KRAS inhibitors for non-small-cell lung cancer
Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany
22 Apr 2020
COVID-19: The management of coronavirus patients with cancer, examples from Ital...
Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
31 Mar 2020
Management of mutation-negative NSCLC
Dr Vijay Patil - Tata Medical Center, Kolkata, India
6 Mar 2020
Systematic therapy of driver mutated NSCLC
Dr Vijay Patil - Tata Medical Center, Kolkata, India
6 Mar 2020
Loco-regionally advanced NSCLC: Radiation oncologist's perspective
Prof Simon Pavamani - Christian Medical College, Vellore, India
6 Mar 2020
